Trial Profile
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients With AML or Acute Leukemia of Ambiguous Lineage
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Dilanubicel (Primary) ; Cytarabine; Filgrastim; Filgrastim; Fludarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nohla Therapeutics
- 21 Nov 2018 Status changed from active, no longer recruiting to discontinued.
- 14 Feb 2017 Planned primary completion date changed from 1 Jun 2017 to 5 Aug 2018.
- 11 Jan 2017 New trial record